Michael Gnant, MD; Allan Lipton, MD; and Gregory R. Mundy, MD, provide an overview of the molecular mechanisms involved in cancer-related bone disease and summarize the latest data on new therapies for preventing cancer treatment–induced bone loss and skeletal-related events in breast cancer patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe key signaling pathways driving the process of bone metastasis
- Cite new findings on the use of bisphosphonates for the prevention of cancer treatment–induced bone loss
- Summarize data on the safety and efficacy of osteoclast inhibitors in treating patients with bone metastases